SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMed Momentum Index: Pause that Refreshes or More Pain to Come?
GERN
|
|
|
+5.04%
in
26 days
Below is a 10-stock BioMed Momentum Index that I have created along with related financial data from Google Finance as of 10/28/09, including the stock price, 52-week change, average daily trading volume, and market cap. I have screened for small and micro-cap stocks with market caps of approximately $500 million (M) or lower with stock price increases of at least 50% in the past year and average trading volume of at least 1M shares per day. <> 1.) Antigenics (NASDAQ: AGEN) ($...
|
Stem Cell Index Surges in Past Week
GERN
|
|
|
-7.70%
in
172 days
(closed on 10/29/09)
<> The stem cell trade was back in a big way over the past week, with several stocks in the <font> ETF Innovators Stem Cell Index </font> registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P Biotech (NYSE:XBI +4%). Hot stocks over the past week among the 40 component companies in the stem cell index include NeoStem (AMEX:NBS) +52.2%, Cytori Therapeutics (NASDAQ:CYTX) +37%, and Geron (NASDAQ:GERN) +22%. Two other widely followed stocks from the index registered smaller gains,...
|
Bullish on GERN ...
GERN
|
|
|
+22.15%
in
245 days
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of c...
|
Stem Cell Index Soars on Lift of Funding Ban
GERN
|
|
|
-36.92%
in
61 days
(closed on 05/10/09)
|
Analysis of Global Stem Cell Index YTD
GERN
|
|
|
+12.07%
in
6 days
(closed on 03/10/09)
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index , which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). <> Below is a profile for each company, including a summary of their b...
|
From the Blogosphere
Geron Will Re-initiate Clinical Trials (NASDAQ:GERN)
|
|
|
Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development ...
|
Earnings highlights: Baidu, Dreamworks, Honda, Microsoft, Target, Verizon ...
Geron Corp. spikes on narrower-than-forecast 3Q loss
Geron: Huge Potential in Oncology, Regenerative Med Pipeline
<>Shares of Geron Corporation (GERN) traded down 10% during early trading on Tuesday due to a report that the FDA placed a clinical hold on the company's investigational new drug application for a cell therapy that treats spinal cord injuries. The FDA, according to the report, placed the hold while it reviewed new information supplied by the company.
Geron has been a great stem cell play for those that have been in the stock since it traded for under two dollars as it reached a high of over nine dollars not too long ago. That being said, the company still has a market cap of nearly $600 mill...
|
Geron Pushes Higher on GE Healthcare Alliance
Geron Corp. (GERN) yesterday traded strongly higher after announcing a collaboration with GE Healthcare to develop and commercialize evaluation technologies from human embryonic stem cells (hESCs). The multi-year collaboration is designed to assist in the discovery of new drugs, their ongoing development and toxicity screening.  The news had shares of Geron soaring up to 22 percent on heavy volume in morning trading, as the collaboration brings another level of legitimacy to Geron’s stem cell program, which has long been clouded by the controversial nature of hESCs.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on GERN |
Visit streetinsider.com
EMGE-Stem Cell Play
- I think the significance of this Press Release has been overlooked, and hope the company has more plans to explain its story:
Emergent Health Corp. (E...
|
More Resources
|
About Geron Corp.
- Answers.com
